Business
Orano Med Enters Next Phase of Collaboration with Roche
PARIS, December 04, 2025--Orano Med enters Next Phase of Collaboration with Roche
About this update from Roche Holding Ltd
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":464,"url":"https://media.zenfs.com/en/business-wire.com/3e35f7516f2144fc049de6960623c0f1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/F09Aklc_TXcsa5lB222jGg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTkyODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/3e35f7516f2144fc049de6960623c0f1","width":480,"height":464}},"lazy":false},{"type":"text","content":"PARIS, December 04, 2025--(BUSINESS WIRE)--Regulatory News:","length":59,"tagName":"p"},{"type":"text","content":"Orano Med, a subsidiary of the Orano group specializing in nuclear medicine, announced today that its long-standing collaboration with the multinational pharmaceutical company Roche (SIX: RO, ROG; OTCQX: RHHBY) is entering the next phase. Over the past years, the companies have conducted extensive preclinical research to develop a potential novel cancer treatment approach called "two-step pretargeted radioimmunotherapy" (or PRIT). This innovative technology, which pretargets the tumor with an antibody that is subsequently able to capture chelated lead-212 (212Pb) to target tumor cells, is now ready to advance into clinical development in humans. Orano Med will be responsible for the manufacturing of 212Pb, utilizing its industrial manufacturing platform in France and the US.","length":795,"tagName":"p"},{"type":"text","content":"Nicolas Maes, Chief Executive Officer of the Orano group, commented: "We are very pleased about the progress made in collaboration with Roche for the development of a potential new treatment approach for cancer patients. After the licensing agreement signed with Sanofi last year for our most advanced clinical program, AlphaMedix™, the achievement with this potential new drug candidate marks an important milestone that we accomplished jointly with another major player in the pharmaceutical industry. It illustrates our capacity to execute our long-term strategy, aimed at developing a solid pipeline of 212Pb-targeted alpha therapies to treat multiple oncology indications. In addition, thanks to the Orano Group’s expertise in the nuclear industry and its access to thorium-232, a scarce raw material required for producing 212Pb, Orano Med is also responsible for the entire production an...